The Inflation Reduction Act’s drug price-setting provisions have drawn significant rebuke from experts who argue that many clinical programs will ultimately be killed or never get started as a result of the act’s deleterious effects on innovation. What isn’t getting attention is how the law is reshaping Medicare in big ways.
top of page
bottom of page
コメント